Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Varlilumab +/- Cobimetinib in Biliary Tract Cancers
NCT04941287Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cobimetinib in biliary tract cancer (BTC), sponsored by National Cancer Institute. Started Dec 2021; status: active, not recruiting.
02
Drugs
cobimetinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04941287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04941287.